Charities have challenged the findings (Image: Kmatta via Getty Images)
Drugs claimed to slow the progression of Alzheimer’s disease “make no meaningful difference to patients” while heightening the risk of swelling and bleeding in the brain, according to a new review. The impact of the medicines on those with early-stage Alzheimer’s and dementia were “either absent or consistently small”, researchers concluded.
However, charities have disputed the findings, arguing that experts have attempted to “paint an entire class of drugs with the same brush” by combining failed drug trials with more recent successful ones. Anti-amyloid medicines work by binding to the protein that accumulates in the brains of Alzheimer’s sufferers, clearing deposits and decelerating cognitive decline.
Yet Edo Richard, professor of neurology at Radboud University Medical Centre in the Netherlands, stated that his team observed results from trials over the past two decades “are not consistent”. Two anti-amyloid drugs – lecanemab and donanemab – are currently licensed for use in the UK.
The treatments were rejected for use on the NHS after the National Institute for Health and Care Excellence (Nice) ruled their benefits “too small” to warrant the cost. The new Cochrane review examined 17 studies involving 20,342 patients in total. The majority had either mild cognitive impairment (MCI), which causes difficulties with thinking and memory, dementia, or both, with a mean age of 70 to 74. The studies encompassed trials on lecanemab and donanemab, as well as aducanumab, which has been discontinued by its manufacturer, and bapineuzumab, crenezumab and solanezumab, which were discontinued following failed trials.
The analysis revealed that the impact of these drugs on cognitive function and dementia severity after 18 months was “trivial”. According to Prof Richard, the differences made by the treatments were “far below the minimal effect that’s needed to be noticeable at all for patients and caregivers”.
A new review has found only ‘small’ benefits (Image: PA)
Read more: Woman left ‘like alien’ after 28 years of cream believes it’s to blame
Read more: Doctor explains feeling sluggish could be symptom of common condition
Francesco Nonino, neurologist and epidemiologist at the IRCCS Institute of Neurological Sciences of Bologna in Italy, said: “Unfortunately, the evidence suggests that these drugs make no meaningful difference to patients. There is now a convincing body of evidence converging on the conclusion that there is no clinically meaningful effect.
“While early trials showed results that were statistically significant, it is important to distinguish between this and clinical relevance. It is common for trials to find statistically significant results that do not translate into a meaningful clinical difference for patients.”
The drugs could also heighten the risk of swelling and bleeding in the brain, according to the research. These side effects were visible in brain scans and produced no symptoms for the majority of patients, although the long-term consequences remained uncertain.
Mr Nonino also pointed out that most studies reported after 18 months, which he described as a “relatively short” window “in the context of a slowly progressive condition like Alzheimer’s”.
“Also it has to be remembered that these drugs in clinical practice may likely be used for much more than 18 months,” he said.
Prof Richard, who runs a dementia clinic, said he was candid with patients about the effect of the approved drugs and that they were “too small for patients and caregivers to notice”. He added that he also drew attention to potential side effects, the requirement for various scans and tests to confirm eligibility, and that patients would need to visit the clinic every two to four weeks to receive the treatment via an IV drip.
He went on to say: “I would tell them… I think you will probably not benefit from these drugs, and they’re burdensome for you and your family. I just think it’s extremely important that we’re honest to our patients about what they can expect… there’s nothing more that I would like as a doctor to finally be able to prescribe them a drug that provides a bit more hope to the patients and their families, but I’m always wary to avoid giving people false hope.”
Responding to the findings, Dr Richard Oakley, associate director of research and innovation at the Alzheimer’s Society, said: “This review’s conclusions make the picture look bleaker than it really is, as authors combined results for a majority of failed drug trials with a small number of more recent successful trials.
“This includes the trials for lecanemab and donanemab which the UK medicines regulator agreed bring a modest but meaningful benefit for people with early-stage Alzheimer’s. It’s essential that we interpret this review with nuance and avoid taking a sledgehammer to decades of pioneering scientific study.”
Jonathan Schott, professor of neurology and group leader of the UK Dementia Research Institute at UCL, said: “By combining studies of different drugs, many of which have long since been disbanded, several of which had little or no effects on beta-amyloid, and most of which have failed in randomised clinical trials, it is almost inevitable that the conclusion will be that as a group they are clinically ineffective.”
Dr Susan Kohlhaas, executive director of research at Alzheimer’s Research UK, stated that the charity routinely heard from families affected by dementia who felt that even a delay of several months in their loved one’s decline “could provide valuable, meaningful time” that “shouldn’t be minimised”.
She said: “Crucially, this study is attempting to paint an entire class of drugs with the same brush even though we know different anti-amyloid treatments can act in different ways.
“Anti-amyloid treatments will not be the whole answer to curing Alzheimer’s and research is already moving towards a wider range of biological targets. But it’s not accurate to dismiss their impact as ‘trivial’, especially when the analysis has clear constraints that limit what it can tell us.”
The assessment follows revelations that Nice is re-examining evidence on donanemab and lecanemab after successful appeals by their respective manufacturers Eli Lilly and Eisai. Areas subject to further scrutiny include the conclusions regarding the quality of life of those caring for Alzheimer’s patients, alongside evidence submitted by NHS England estimating the cost of administering the treatments by infusion.
